Document is current

Article History

Received: 27 January 2025

Accepted: 5 March 2025

First Online: 27 March 2025

Declarations

:

: Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Anna Dudek, Wojciech Baran, Mariusz Sikora, and Marek Krogulec were study investigators in the presented CT-P17 3.3. study and have no other conflicts of interest to declare. David M. Pariser was a study investigator in the presented CT-P17 3.3. study, has personally received honorarium for participating in a data safety monitoring board for Bristol Myers Squibb, and has received institutional research funding from Novartis, Pfizer, and Regeneron. Mark G. Lebwohl is an employee of Mount Sinai, was a study investigator in the presented CT-P17 3.3. study, receives research funding from AbbVie, Arcutis Biotherapeutics, Avotres Inc., Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte Corporation, Inozyme Pharma, Janssen Pharmaceuticals, Pfizer, Sanofi/Regeneron, and UCB, and is a consultant for Almirall, AltruBio, Apogee Therapeutics, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres Inc., Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte Corporation, LEO Pharma, Meiji Seika Pharma, Mindera Health, Mirum Pharmaceuticals, Pfizer, Sanofi/Regeneron, Seanergy Pharma, Strata, Takeda, Trevi Therapeutics, and Verrica Pharmaceuticals. Mark G. Lebwohl is an Editorial Board member of Dermatology and Therapy. Mark G. Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Witold Owczarek was a study investigator in the presented CT-P17 3.3. study and has received honorarium for lectures and clinical research from AbbVie, Aflofarm Farmacja, Alfasigma, Almirall, Amgen, Apotex Polska, Astellas, AstraZeneca, Bausch Health Poland, Berlin Chemie Menarini, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Egis Pharmaceuticals, Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma, Medac GmbH, Merck, Mylan Healthcare, Novartis, Pfizer, Pierre Fabre Medicament, TZF Polfa S.A., Roche Diagnostics, Sandoz, Sanofi, SUN-FARM, Teva Pharmaceuticals, and UCB Pharma. Pawel Brzewski was a study investigator in the presented CT-P17 3.3 study and has received honorarium and/or consultation fees from AbbVie, Amgen, Concert Pharmaceuticals, Eli Lilly, Innovaderm Research, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Samsung, and Sanofi Genzyme. SungHyun Kim, JeeHye Suh, EunJin Choi, JungBin Cha, HyunJin Lee, and SungJeong Lee are employees of Celltrion, Inc. John Y. Koo was a study investigator in the presented CT-P17 3.3. study, has received speaker honorarium from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Janssen Pharmaceuticals, Eli Lilly, LEO Pharma, Pfizer, Sanofi/Regeneron, SUN Pharma, and UCB, and has advised Arcutis, LEO Pharma, and Pfizer.

: The study was conducted in accordance with the principles of the Declaration of Helsinki 1964 and Good Clinical Practice. All aspects of the study complied with national, state, and local laws. Institutional review boards and ethics committees are reported in Supplementary Material (Table S1). Patients provided informed consent to participate. WRO MEDICA, Poland, acted as the master ethics committee.